 Print page |
 Email page |
Florida Court Ruling has implications for physician's prescribing practice
A Florida State administrative judge ordered that levothyroxine sodium be taken off of the negative formulary list which had previously protected brand name thyroid hormone prescriptions
(February 20, 2008)
The ATA Unveils New Data to FDA On Bioequivalence of Levothyroxine
Physician survey reveals significant adverse events in patients
(October 4, 2006)
ATA letter to FDA regarding retitration
for patient well-being
ATA expresses concern to FDA regarding deletion of
retitration warning after switching brands
(August 3, 2005)
ATA follows up on May 23 FDA workshop
ATA
writes letter to follow-up after FDA workshop
(June 30, 2005)
Agenda of Joint Public Meeting -
ATA,The Endocrine Society, AACE and the FDA
Joint
Public Meeting on Equivalence of Levothyroxine Sodium Products
- Agenda (PDF File, 27KB)
(May 23, 2005)
Streaming Video of bioequivalence
workshop
ATA, AACE
and The Endocrine Society hold workshop with FDA officials
(May 23, 2005)
FDA hosts Public Meeting for Levothyroxine
Therapeutic Equivalence
FDA
hosts workshop
(April 22, 2005, updated July 22, 2005)
FDA workshop on bioequivalence announced
in Federal Register
FDA
workshop on bioequivalence co-sponsored by the ATA, The Endocrine
Society, and AACE
(April 20, 2005)
Thyroxine Products Joint Position
Statement
AACE, TES,
and ATA Joint Position Statement on the Use and Interchangeability
of Thyroxine Products
(December 8, 2004)
The Medical Letter
Medical
Letter responds to Generic Levothyroxine Issue
(September 27, 2004)
Thyroid Experts Warning
Thyroid
Experts Warn of Clinically Important Differences in Potency of
FDA-Approved Levothyroxine Products
(August 11, 2004)
Thyroid Experts Speak Out
Thyroid
Experts Speak Out Against the FDA’s Decision to Approve
Generic Levothyroxine Preparations
(June 28, 2004)
Professional endocrine societies
concerned for patient health
ATA, TES, and
AACE express disappointment and concern for the health of millions
of thyroid patients after FDA announces decision to approve generic
substitutes for levothyroxine product
(June 24, 2004)
FDA urged to consider health of
millions of thyroid patients
ATA and Endocrine Sister
Societies urge FDA to consider expert opinion and the health of
millions of thyroid patients
(May 26, 2004)
FDA postpones bioequivalence workshop
ATA, AACE and
TES respond to FDA postponement of workshop
(March 19, 2004)
FDA plans workshop with Professional
endocrine societies
FDA Bioequivalence Workshop
Plans continue with ATA, Endocrine Society and AACE leaders
(December 30, 2003)
Agenda for levothyroxine workshop
Draft
Levothyroxine Workshop Agenda (PDF File)
FDA invites Professional endocrine
societies to thyroxine bioequivalence workshop
FDA invites ATA,
TES & AACE to Plan Workshop on Thyroxine Bioequivalence
(November, 5, 2003)
ATA continues dialog with FDA on
dose precision
ATA Continues
Dialog With FDA on Levothyroxine Dose Precision and Bioequivalence
Standards
(October 1, 2003)
ATA asks FDA to ensure safety and
effectiveness of levothyroxine preparations
ATA
asks the FDA to ensure safe and effective levothyroxine preparations
(April 4, 2003)
